Kymera Therapeutics, Inc. (KYMR) stock
KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30241% above fair value
$121.52−4.33 (-3.44%)
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Kymera Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Kymera Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -396.0%. For fiscal 2025 it was -891.1%, against -555.8% the year before. The highest annual figure on record is -136.1% in fiscal 2020.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -891.1% | −335.3 |
| FY2024 | Dec 31, 2024 | -555.8% | −345.2 |
| FY2023 | Dec 31, 2023 | -210.6% | +133.8 |
| FY2022 | Dec 31, 2022 | -344.4% | −206.3 |
| FY2021 | Dec 31, 2021 | -138.0% | −2.0 |
| FY2020 | Dec 31, 2020 | -136.1% | +1302.4 |
| FY2019 | Dec 31, 2019 | -1438.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -116.3% | +620.5 |
| Q1 FY2026 | Mar 31, 2026 | -244.9% | +91.9 |
| Q4 FY2025 | Dec 31, 2025 | -3411.0% | −2318.8 |
| Q3 FY2025 | Sep 30, 2025 | -3347.4% | −1419.4 |
| Q2 FY2025 | Jun 30, 2025 | -736.8% | −538.3 |
| Q1 FY2025 | Mar 31, 2025 | -336.8% | +225.4 |
| Q4 FY2024 | Dec 31, 2024 | -1092.2% | −1051.8 |
| Q3 FY2024 | Sep 30, 2024 | -1927.9% | −711.6 |
| Q2 FY2024 | Jun 30, 2024 | -198.5% | +64.2 |
| Q1 FY2024 | Mar 31, 2024 | -562.2% | −83.3 |
| Q4 FY2023 | Dec 31, 2023 | -40.3% | +199.0 |
| Q3 FY2023 | Sep 30, 2023 | -1216.3% | −746.4 |
| Q2 FY2023 | Jun 30, 2023 | -262.7% | +91.7 |
| Q1 FY2023 | Mar 31, 2023 | -478.8% | −95.0 |
| Q4 FY2022 | Dec 31, 2022 | -239.4% | −16.8 |
| Q3 FY2022 | Sep 30, 2022 | -469.9% | −329.1 |
| Q2 FY2022 | Jun 30, 2022 | -354.4% | −220.9 |
| Q1 FY2022 | Mar 31, 2022 | -383.8% | −313.4 |
| Q4 FY2021 | Dec 31, 2021 | -222.5% | −122.6 |
| Q3 FY2021 | Sep 30, 2021 | -140.8% | −85.2 |
| Q2 FY2021 | Jun 30, 2021 | -133.5% | +298.1 |
| Q1 FY2021 | Mar 31, 2021 | -70.4% | +257.7 |
| Q4 FY2020 | Dec 31, 2020 | -100.0% | +542.8 |
| Q3 FY2020 | Sep 30, 2020 | -55.6% | +1192.9 |
| Q2 FY2020 | Jun 30, 2020 | -431.6% | – |
| Q1 FY2020 | Mar 31, 2020 | -328.1% | – |
| Q4 FY2019 | Dec 31, 2019 | -642.8% | – |
| Q3 FY2019 | Sep 30, 2019 | -1248.5% | – |
See a number that looks wrong?